scholarly journals Metabolic syndrome and chronic heart failure: a modern aspect of the problem

2022 ◽  
Vol 21 (1) ◽  
pp. 105-113
Author(s):  
Tatiana Fedorova ◽  
Natalya Semenenko ◽  
Serafima Tazina ◽  
Alexander Mamonov ◽  
Tatiana Sotnikova
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Chronic Heart Failure ◽  
Clinical Course ◽  
Rapid Development ◽  
Medical Science ◽  
Left Ventricular ◽  
Modern Aspect ◽  
Functional Changes

Objective: The increase of morbidity results from both an increase of life expectancy of the population, and influence of various risk factors contributing to development and increase of chronic heart failure (CHF). The combination of several atherogenic mechanisms (abdominal obesity (AO), insulin resistance (IR), arterial hypertension (AH), hyperglycemia, dyslipidemia), combined as “metabolic syndrome” (MS), causes a more rapid development of CHF. Materials and methods: The research finding of 74 patients with class II-III of CHF, including 37 patients (50%) with MS, are presented. The age structure of the pathology, severity of clinical course, data of laboratory and instrumental examination in various groups of patients were evaluated. A special program included an echocardiographic test with an assessment of various myocardial parameters. Results and Discussion: Research materials find out a number of characteristics of CHF clinical course (its earlier development and severe course) in patients with MS. Echocardiographic tests reveal an increase of heart chambers sizes, thickness of left and right ventricle, pulmonary hypertension. Myocardium morpho-functional changes are more significant in patients with CHF and MS than in those without MS. An increase in leptin levels, a marker of obesity, fibrosis and inflammation, has been found. Leptin, C-reactive peptide (CRP) and high-sensitive troponin in patients with MS significantly exceeded those in patientswithout MS. Correlations of leptin levels, adiponectin, CRP and left ventricular mass, thickness of epicardial fat (TEF), ejection fraction were established. Conclusion: Materials of the research indicate the important role of inflammatory and dysmetabolic processes in development and progression of CHF in patients with MS. Bangladesh Journal of Medical Science Vol. 21(1) 2022 Page : 105-113

The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients

2018 ◽  
Vol 7 (4) ◽  
pp. 5
Author(s):  
A. P. Roytman ◽  
T. A. Fedorova ◽  
E. A. Ivanova ◽  
A. V. Bugrov ◽  
V. V. Dolgov
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Chronic Heart Failure ◽  
Myocardial Injury

Cardiac and vascular ageing

2017 ◽  
pp. 729-736
Author(s):  
Hidetaka Ota ◽  
Masahiro Akishita
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
Chronic Heart Failure ◽  
Left Ventricular Hypertrophy ◽  
Blood Vessels ◽  
Left Ventricular ◽  
Functional Changes ◽  
Healthy Humans ◽  
Vascular Ageing

There is a continuum of expression of cardiac structural and functional alterations that occurs with ageing in healthy humans, and these age-associated cardiac changes seem to be relevant to the increase in left ventricular hypertrophy, chronic heart failure, and arrhythmia that are commonly observed with increasing age. This chapter describes the structural and functional changes in the ageing process of the heart and blood vessels, and provides an overview of representative cardiovascular disease caused by ageing including hypertension, atherosclerosis, and heart failure. In addition, an outline of interventions that have be utilized to prevent and treat ageing related cardiovascular diseases is provided.

scholarly journals Pathogenetic treatment of chronic heart failure: the role of torasemide

2015 ◽  
Vol 12 (3) ◽  
pp. 56-62
Author(s):  
N B Perepech
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Diastolic Dysfunction ◽  
Clinical Studies ◽  
Clinical Manifestations ◽  
Left Ventricular ◽  
Filling Pressure ◽  
Ventricular Filling Pressure ◽  
Ventricular Filling

The article discusses the torasemide pharmacokinetic characteristics which are favourably different from furosemide characteristics. We paid attention to the fact that torasemide had anti-aldosteronic and antifibrotic effects; all these characteristics were alien to other diuretics nature. The results of clinical studies showed torasemide ability to prevent the development and reverse myocardial fibrosis. Taking into account modern representations concerning the pathogenesis of chronic heart failure, in particular the role of diastolic dysfunction in developing haemodynamic compromise, we substantiated torasemide application as a part of complex pharmacotherapy of chronic heart failure in patients with elevated left ventricular filling pressure before the appearance of clinical manifestations of stagnation.

scholarly journals Identification of High-Risk Chronic Heart Failure Patients in Clinical Practice: Role of Changes in Left Ventricular Function

2012 ◽  
Vol 35 (9) ◽  
pp. 580-584 ◽  
Author(s):  
Mariantonietta Cicoira ◽  
Andrea Rossi ◽  
Andrea Chiampan ◽  
Giulia Frigo ◽  
Corinna Bergamini ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Practice ◽  
High Risk ◽  
Chronic Heart Failure ◽  
Left Ventricular Function ◽  
Ventricular Function ◽  
Left Ventricular ◽  
Heart Failure Patients

scholarly journals Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders

2019 ◽  
Vol 91 (1) ◽  
pp. 32-37 ◽  
Author(s):  
E V Grakova ◽  
K V Kopeva ◽  
A T Teplyakov ◽  
O N Ogurkova ◽  
A A Garganeeva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Carbohydrate Metabolism ◽  
Serum Levels ◽  
Left Ventricular ◽  
Type 2 Dm ◽  
Group 2 ◽  
Group 1

Aim. To study the role of soluble ST2 (sST2) in patients with coronary artery disease (CAD) and chronic heart failure (CHF) associated with carbohydrate metabolism disorders (impaired glucose tolerance (IGT) and type 2 diabetes mellitus (DM) in risk stratification of adverse cardiovascular events (ACE) for 12 months of follow-up. Materials and methods. We enrolled 118 patients with CAD and CHF I-III FC (NYHA) with the ejection fraction of left ventricular of 60 [46; 64] % aged 62.5 [57; 68] years. Serum sST2 levels were measured by enzyme immunoassay. Results. Depending on the presence of carbohydrate metabolism disorders (CMD), the patients were divided into 3 groups: group 1 (n=65) included patients without CDM, group 2 (n=30) included with IGT, and group 3 (n=23) included with type 2 DM. Serum levels of sST2 in patients with CMD were significantly (p=0.011) higher than in patients without CMD, but in subgroups of patients with IGT and type 2 DM, the concentrations of sST2 did not differ. In group 1 sST2 levels were 30.51 [26.38; 37.06] ng/ml, and in group 2 and 3 - 37.97 [33.18; 47.48] and 41.45 [35.27; 50.37] ng/ml, respectively. There were statistically significant differences in the rate of adverse ACE in relation to sST2 levels: in spite of CMD, in subgroups with biomarker overexpression adverse CCC occurred more often (p

scholarly journals CHARACTERISTICS OF CLINICAL CURRENT AND STRUCTURAL-FUNCTIONAL STATE OF LEFT VENTRICULAR IN DECOMPENSATION OF CHRONIC HEART FAILURE IN PATIENTS WITH ISCHEMIC CHRONIC HEART FAILURE WITH SYSTOLIC DYSFUNCTION AND INFLAMMATION OF THE MYOCARDIUM

2018 ◽  
Vol 33 (2) ◽  
pp. 26-34
Author(s):  
E. V. Kruchinkina ◽  
T. R. Ryabova ◽  
Yu. V. Rogovskaya ◽  
R. E. Batalov ◽  
V. V. Ryabov
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Functional State ◽  
Clinical Course ◽  
Systolic Dysfunction ◽  
Interventricular Septum ◽  
Myocardial Revascularization ◽  
Left Ventricular ◽  
Volume Index ◽  
Myocardial Inflammation

The aimwas to study the clinical course of CHF decompensation and the structural and functional state of the left ventricle in patients with ischemic CHF with systolic dysfunction and myocardial inflammation.Material and Methods.This study is open, non-randomized, prospective, registered on the ClinicalTrials.gov website, identification number: NCT02649517. The analysis included 25 patients (84% men, LVEF 29.17±9.4%) with ADHF of ischemic etiology. The average age of the patients was 60.12±9.3 years. All the patients underwent an echocardiography including 2D-speckle tracking technique to assess LV deformation. All patients underwent invasive coronary angiography to exclude the progression of coronary atherosclerosis, as a cause of CHC decompensation. An endomyocardial biopsy was performed to diagnose the presence of myocardial inflammation. We performed a comparative analysis of clinical, laboratory, instrumental indicators depending on the fact of diagnosis of inflammation in the myocardium.Results.There were no specific features of the clinical course of decompensation of ischemic CHF with systolic LV dysfunction depending on the inflammation in the myocardial tissue. However, in patients with inflammation, aortocoronary bypass surgery was more often performed (p=0.00650). In addition, in patients with inflammation, there was a decrease in apical rotation (p=0.0313), its systolic velocity (p=0.0157 with decompensation of CHF. A year later, improvement in LV biomechanics, but a continuing decrease in the absolute modulus of global longitudinal LV deformation (p=0.0431) after the anti-inflammatory treatment. Also a year later, in both groups there was an increase in the LV end-diastolic volume index (p=0.0180 and p=0.0280, respectively), a decrease in the interventricular septum of the LV (p=0.0491) in the group with inflammation, and an increase in the myocardial mass index of the LV (p=0.04995) in patients with inflammation.Conclusion.Decreased apical LV rotation and its systolic velocity in patients with ischemic CHF and LV systolic dysfunction, in view of the lack of clinical improvement after optimal myocardial revascularization, may be an additional criterion of concomitant inflammation in the myocardium. Among patients with ischemic CHF and LV systolic dysfunction, more pronounced cardiac remodeling, manifested by LV dilatation and thinning of LV wall, was observed in the group with inflammation.

Sign in / Sign up

Export Citation Format

Share Document